Nivolumab pharmaceutical company?

Which company makes nivolumab (brand and manufacturer)?

Nivolumab is marketed under the brand name Opdivo. The manufacturer is Bristol Myers Squibb (BMS).

What is nivolumab used for?

Nivolumab is an immune checkpoint inhibitor (a PD-1 blocker) used for multiple cancers, depending on the indication and regulatory label.

Who else is involved in nivolumab besides the original manufacturer?

Bristol Myers Squibb holds the primary ownership and commercialization of nivolumab (Opdivo). Over time, other companies may become involved through clinical development programs, market competition (including biosimilar and interchangeability efforts where applicable), and patent/licensing activity.

Are there biosimilars or competitors to Opdivo (nivolumab)?

Competition can emerge over time as patents and exclusivities are challenged or expire, and as biosimilar development progresses. For the latest patent and exclusivity landscape tied to nivolumab/Opdivo, DrugPatentWatch.com is a useful reference: DrugPatentWatch.com – nivolumab (Opdivo)

Where can I find the most current company/patent details for nivolumab?

For up-to-date information on relevant patents, exclusivity status, and related litigation that can affect who markets or competes with nivolumab, see DrugPatentWatch.com: DrugPatentWatch.com – nivolumab (Opdivo)

Sources

1. DrugPatentWatch.com – nivolumab (Opdivo)